Quarterly ResultAug 5, 2026, 08:15 AM
UroGen Q2 Revenue $72.46M, Net Loss $(14.35)M; EPS $(0.28)
AI Summary
UroGen Pharma Ltd. reported a significant increase in revenue and a substantial reduction in net loss for the second quarter of 2026. Revenue rose to $72.46 million, up from $24.22 million in the prior year, while net loss improved to $(14.35) million from $(49.94) million. The company achieved positive operating income for the quarter. Despite these operational improvements, total liabilities and the accumulated deficit increased, and long-term debt grew to $188.73 million.
Key Highlights
- Revenue for Q2 2026 increased to $72.46 million from $24.22 million in Q2 2025.
- Net loss for Q2 2026 significantly reduced to $(14.35) million from $(49.94) million in Q2 2025.
- Diluted EPS improved to $(0.28) in Q2 2026 from $(1.05) in Q2 2025.
- Operating income for Q2 2026 was $0.11 million, compared to an operating loss of $(41.45) million in Q2 2025.
- Total assets increased to $252.59 million as of June 30, 2026, from $200.46 million at year-end 2025.
- Long-term debt increased to $188.73 million as of June 30, 2026, from $122.21 million at year-end 2025.
- Accumulated deficit grew to $(997.64) million as of June 30, 2026, from $(959.72) million at year-end 2025.
Price Impact
More from URGN